Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: A phase II metabolite as a perpetrator of drug-drug interactions

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 4, 2014, Pages 498-507

  Tornio, A ^a,b   Filppula, A M ^a   Kailari, O ^a   Neuvonen, M ^a   Nyronen T H ^a   Tapaninen, T ^a,b   Neuvonen, P J ^a,b   Niemi, M ^a,b   Backman, J T ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; CARBAMIC ACID DERIVATIVE; CLOPIDOGREL; CYP2C8 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; GLUCURONIDE; PIPERIDINE DERIVATIVE; REPAGLINIDE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL; COMPUTER SIMULATION; DRUG DETOXIFICATION; DRUG INTERACTION; ENZYME ACTIVE SITE; FEMALE; HUMAN; MALE; METABOLISM; MOLECULAR DOCKING; TIME;

ARYL HYDROCARBON HYDROXYLASES; CARBAMATES; CATALYTIC DOMAIN; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC DETOXICATION, PHASE II; MOLECULAR DOCKING SIMULATION; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TIME FACTORS;

EID: 84921630257     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.141     Document Type: Article

References (36)

1. Holmberg, M.T., Tornio, A., Neuvonen, M., Neuvonen, P.J., Backman, J.T. & Niemi, M. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin. Pharmacol. Ther. 95, 307-313 (2014).
2. Farid, N.A., Kurihara, A. & Wrighton, S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50, 126-142 (2010).
3. Simon, T. et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
4. Backman, J.T., Kyrklund, C., Neuvonen, M. & Neuvonen, P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685-691 (2002).
5. Staffa, J.A., Chang, J. & Green, L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346, 539-540 (2002).
6. Floyd, J.S. et al. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin. Pharmacol. Ther. 91, 896-904 (2012).
7. Tamraz, B. et al. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet. Genomics 23, 355-364 (2013).
8. Kalliokoski, A. & Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705 (2009).
9. Totah, R.A. & Rettie, A.E. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77, 341-352 (2005).
10. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011).
11. Niemi, M. et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77, 468-478 (2005).
12. Niemi, M., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347-351 (2003).
13. Huang, S.M., Temple, R., Throckmorton, D.C. & Lesko, L.J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther. 81, 298-304 (2007).
14. Schoch, G.A., Yano, J.K., Sansen, S., Dansette, P.M., Stout, C.D. & Johnson, E.F. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J. Biol. Chem. 283, 17227-17237 (2008).
15. Pinheiro, L.F. et al. Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int. J. Cardiol. 158, 125-129 (2012).
16. Honkalammi, J., Niemi, M., Neuvonen, P.J. & Backman, J.T. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab. Dispos. 39, 1977-1986 (2011).
17. Honkalammi, J., Niemi, M., Neuvonen, P.J. & Backman, J.T. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin. Pharmacol. Ther. 91, 846-855 (2012).
18. Tornio, A. et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin. Pharmacol. Ther. 84, 403-411 (2008).
19. Backman, J.T. et al. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab. Dispos. 37, 2359-2366 (2009).
20. Daily, E.B. & Aquilante, C.L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10, 1489-1510 (2009).
21. Ogilvie, B.W. et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 34, 191-197 (2006).
22. Shitara, Y., Hirano, M., Sato, H. & Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004).
23. Ding, Z., Kim, S., Dorsam, R.T., Jin, J. & Kunapuli, S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101, 3908-3914 (2003).
24. Richter, T. et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308, 189-197 (2004).
25. Turpeinen, M., Tolonen, A., Uusitalo, J., Jalonen, J., Pelkonen, O. & Laine, K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin. Pharmacol. Ther. 77, 553-559 (2005).
26. Zhang, H., Amunugama, H., Ney, S., Cooper, N. & Hollenberg, P.F. Mechanismbased inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme. Mol. Pharmacol. 80, 839-847 (2011).
27. Ha-Duong, N.T., Dijols, S., Macherey, A.C., Goldstein, J.A., Dansette, P.M. & Mansuy, D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40, 12112-12122 (2001).
28. VandenBrink, B.M. & Isoherranen, N. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr. Opin. Drug Discov. Devel. 13, 66-77 (2010).
29. Yeung, C.K., Fujioka, Y., Hachad, H., Levy, R.H. & Isoherranen, N. Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin. Pharmacol. Ther. 89, 105-113 (2011).
30. Baer, B.R., DeLisle, R.K. & Allen, A. Benzylic oxidation of gemfibrozil-1-O-betaglucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem. Res. Toxicol. 22, 1298-1309 (2009).
31. Jenkins, S.M. et al. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. Drug Metab. Dispos. 39, 2421-2430 (2011).
32. Lai, X.S., Yang, L.P., Li, X.T., Liu, J.P., Zhou, Z.W. & Zhou, S.F. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr. Drug Metab. 10, 1009-1047 (2009).
33. Filppula, A.M., Laitila, J., Neuvonen, P.J. & Backman, J.T. Potent mechanismbased inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br. J. Pharmacol. 165, 2787-2798 (2012).
34. Silvestro, L. et al. Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. Anal. Bioanal. Chem. 401, 1023-1034 (2011).
35. Jones, D.R., Gorski, J.C., Hamman, M.A., Mayhew, B.S., Rider, S. & Hall, S.D. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther. 290, 1116-1125 (1999).
36. Kitz, R. & Wilson, I.B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 237, 3245-3249 (1962).